hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas

Liu, Yang

doi:10.3892/mmr.2011.621

Cited by 41 publications

(44 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the inhibitory effect on metastasis in hepatoma carcinoma cells, induced by the suppression of miR-96 [107], was reported as being associated with the inhibition of EFNA5 expression by miR-96-targeting [85]. Similar findings have been reported in case of gastric, bladder, and breast cancers [3, 7, 83, 108]. With regard to miR-182, Huynh et al reported significant suppression of invasive growth tendency and metastasis by suppressing miR-182 in vivo [109].…”

Section: Resultsmentioning

confidence: 55%

Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

Liang

Fan

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Previous studies have reported aberrant expression of the miR-183-96-182 cluster in a variety of tumors, which indicates its' diagnostic or prognostic value. However, a key characteristic of the miR-183-96-182 cluster is its varied expression levels, and pleomorphic functional roles in different tumors or under different conditions. In most tumor types, the cluster is highly expressed and promotes tumorigenesis, cancer progression and metastasis; yet tumor suppressive effects have also been reported in some tumors. In the present study, we discuss the upstream regulators and the downstream target genes of miR-183-96-182 cluster, and highlight the dysregulation and functional roles of this cluster in various tumor cells. Newer insights summarized in this review will help readers understand the different facets of the miR-183-96-182 cluster in cancer development and progression.

show abstract

Section: Resultsmentioning

confidence: 55%

Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

Liang

Fan

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…miR-96 was identified as the most significantly up-regulated miR, and miR-490-5p was the most significantly down-regulated miR. Wang et al confirmed increased expression of miR-96 in BC compared with normal tissue and demonstrated that this miR species increased cellular proliferation and invasion in the human BC cell line T24, possibly through induction of IRS1, a protein involved in insulin signaling, and MAP4K1, which belongs to the STE/Ser/Thr protein kinase family and mediates growth regulation and environmental stress response [26]. …”

Section: Resultsmentioning

confidence: 99%

The evolving understanding of microRNA in bladder cancer

Guancial

Bellmunt

Yeh

et al. 2014

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Purpose MicroRNA (miR) expression is altered in urologic malignancies, including bladder cancer (BC). Individual miRs have been shown to modulate multiple signaling pathways that contribute to BC. We reviewed the primary literature on the role of miRs in BC and provide a general introduction to the processing, regulation, and function of miRs as tumor suppressors and oncogenes; and critically evaluate the literature on the implications of altered miR expression in BC. Materials and Methods We searched the English language literature for original and review articles in PubMed® from 1993 to March 2013, using the terms “microRNA” and “bladder cancer,” “transitional cell carcinoma,” or “urothelial carcinoma.” This search yielded 133 unique articles with greater than 85% published within the last three years. Results To date, the majority of miR studies in BC use profiling to describe dynamic changes in miR expression across stage and grade. Generalized down regulation of miRs, including those that target the fibroblast growth factor 3 (FGFR3) pathway such as miR-145, miR-101, miR-100 and miR-99a, has been observed in low grade, non-muscle invasive bladder cancer (NMIBC). In contrast, generalized increased expression of miRs is observed in high grade, muscle invasive bladder cancer (MIBC) compared with adjacent normal bladder urothelium, including miRs predicted to target p53, such as miR-21 and miR-373. Furthermore, p53 suppresses transcriptional factors which promote mesenchymal differentiation, ZEB-1 and ZEB-2, through regulation of the miR200 family. Conclusions Aberrations in miR expression identified between NMIBC and MIBC support and provide insight into molecular alterations known to distinguish the two parallel pathways of bladder carcinogenesis. The heterogeneity of tumor specimens and research methods limits the reproducibility of changes in miR expression profiles between studies and underscores the importance of in vivo validation in a field that utilizes in silico miR target prediction models.

show abstract

“…In our study, we used the Hyaluronoglucosaminidase 1 gene as a starting point to generate a list of regulatory genes, in a ranking order of highest prediction, using relevant data bases. In addition, we selected lncRNA and miRNAs which were previously published in BC [9][10][11] and were reported to target HYAL1. Then, we performed pathway enrichment analysis and multiple sequence alignment to explore the intersected signaling pathways and their evolutionary relationship.…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies, associations between BC and several biomarkers such as lncRNA-UCA1 [9], miR-210 [10], miR-96 [11], miRNA-220, or Hyaluronoglucosaminidase 1 [12] were identified.…”

Section: Introductionmentioning

confidence: 99%

Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis

et al. 2015

View full text Add to dashboard Cite

Early screening for bladder cancer (BC) holds the key to combat and control the increasing global burden of BC mortality. We presented a simple approach to characterize, analyze, and validate a panel of biomarkers in BC and their relationship to bilharziasis. We investigated voided urine and blood samples from patients with bladder cancer (n = 94), benign bladder lesions (n = 60), and age-matched normal controls (n = 56). This study was divided into the following phases. (1) We analyzed the expression of urinary Hyaluronoglucosaminidase 1 (HYAL1) protein in BC and control samples by zymography. (2) We performed bioinformatics analysis to retrieve a set of epigenetic regulators of HYAL1. (3) This set of three selected genes [long non-coding RNA-urothelial cancer associated 1(lncRNA-UCA1), microRNA-210, and microRNA-96] was then analyzed in the same urine samples used in phase I by quantitative real-time PCR. (4) A high reproducibility of gene selection results was also determined from statistical validation. The urinary expression of HYAL1 protein and its epigenetic regulators were higher in BC patients (P < .001). The receiver-operating characteristic curve analyses demonstrated that each one had good sensitivity and specificity for distinguishing BC patients from non-BC ones (HYAL1, 89.4 and 91.2 %; miR-210, 76.6 and 93 %; miR-96, 76.6 and 89.4 %; and lncRNA-UCA1, 91.5 and 96.5 %). There was a significant positive correlation between HYAL1 and the selected epigenetic biomarkers. The performance of this urine biomarker panel reached 100 % sensitivity and 89.5 % specificity for bladder cancer diagnosis.

show abstract

hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas

Cited by 41 publications

References 19 publications

Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis

The evolving understanding of microRNA in bladder cancer

Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis

Contact Info

Product

Resources

About